Date:6/4/2010

2009 2009 2010 RMB RMB RMB US$ As adjusted (5) (in thousands except for per ADS information) Revenues, net (1) 248,635 172,320 175,728 25,745 Cost of revenues (2) (61,834) (62,996) (61,624) (9,028) Gross profit 186,801 109,324 114,104 16,717 Operating expenses: Research and development (2)(3) (10,670) (10,738) (10,352) (1,517) Acquired in-process research and development -- -- -- -- Sales and marketing (2) (11,963) (19,058) (16,695) (2,446) General and administrative (2)(3) (20,538) (25,844) (26,743) (3,918) Amortization of SPR intangible assets (2) (27,379) (27,343) (27,343) (4,006) Total operating expenses (70,550) (82,983) (81,133) (11,887) Operating income 116,251 26,341 32,971 4,830 Interest income 5,608 4,332 4,155 609 Interest expense - convertible notes (5) (34,993) (35,421) (34,831) (5,103) Interest expense - amortization of convertible notes issuance costs (5) (4,383) (4,378) (4,263) (624) Interest expense - other (785) -- -- -- Other income/ (expense), net (168) 225 26,267 3,848 Income/ (loss) before income tax 81,530 (8,901) 24,299 3,560 Income tax expense (32,143) (13,088) (15,206) (2,228) Income/ (loss) from continuing operations 49,387 (21,989) 9,093 1,3
'/>"/>

SOURCE China Medical Technologies, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
Related medicine technology :

1. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
2. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
3. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
4. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
5. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
6. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
7. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
8. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
9. China Animal Welfare Law Under Review While 36,000 Dogs Culled
10. China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock
11. Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth